Skip to main content
Smart Investors Daily
MT

AMEX · MTNB

Matinas BioPharma Holdings, Inc.

Healthcare · Biotechnology

$1.70

Down-$0.01 (-0.55%)

Updated Oct 24, 2026, 7:35 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.4M
P/E ratio
-0.25
Dividend yield
0.00%
52-week range
$0.15 – $3.15
Volume
11.29K
Avg. volume
38.35K

Price performance · MTNB

MTNB price history

1M range · 0 trading sessions · Daily adjusted prices

MTNB does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MTNB news

The latest Smart Investors Daily articles mentioning MTNB.

MTNB research

Overview

Company profile and research snapshot.

Company profile

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$30.60
Implied upside
—
Analysts
7
MTNB recent ratings
DateFirmRatingTarget
Oct 31, 2024Maxim GroupHold—
Oct 11, 2023BTIGBuy—
Jan 31, 2023HC Wainwright & Co.Buy—
Aug 13, 2020Aegis CapitalBuy—
Jan 27, 2020Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output

Agreement establishes GH Power’s first commercial hydrogen offtake and validates hydrogen production from the Company’s proprietary aluminum-water reactor platformToronto, Canada, Sept. 14, 2026 (GLOBE NEWSWIRE) -- GH Power Inc. (“GH Power” or the “Company”) (NYSE American: MTNB), a Canadian clean energy and critical materials technology company, today announced that it has entered into a multi-year hydrogen supply agreement (the “Agreement”) with Change Energy Engineering Inc. on behalf of its

Yahoo · Sep 4, 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.